🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
12/01/2023 1,4800 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/09/2022 142,07 143,42 140,95 143,06 +0,03% 1,74% 5.751.600
22/09/2022 140,21 144,46 140,00 143,01 +1,92% 3,18% 6.161.000
21/09/2022 142,15 143,63 140,29 140,31 -1,03% 2,35% 5.076.100
20/09/2022 141,82 142,49 140,37 141,77 -0,62% 1,49% 4.532.900
19/09/2022 143,64 143,86 141,43 142,66 -0,97% 1,69% 5.042.500
16/09/2022 143,40 144,85 141,36 144,06 +1,09% 2,43% 13.887.500
15/09/2022 139,99 143,90 139,39 142,51 +2,12% 3,22% 6.416.900
14/09/2022 139,17 140,44 138,27 139,55 +0,74% 1,56% 4.673.600
13/09/2022 140,55 141,93 137,49 138,53 -2,61% 3,16% 6.195.900
12/09/2022 141,01 142,87 140,32 142,24 +0,58% 1,81% 4.938.400
09/09/2022 140,40 142,17 140,10 141,42 +0,64% 1,47% 4.427.000
08/09/2022 139,64 140,57 138,65 140,52 +1,30% 1,37% 3.988.300
07/09/2022 137,55 139,04 135,34 138,71 +0,81% 2,69% 4.141.700
06/09/2022 137,30 139,35 136,24 137,59 +0,96% 2,27% 4.810.600
02/09/2022 138,66 139,40 135,81 136,28 -1,57% 2,59% 3.601.600
01/09/2022 134,64 138,59 134,10 138,45 +2,97% 3,33% 4.521.000
31/08/2022 135,69 136,04 134,17 134,46 -0,80% 1,38% 5.789.600
30/08/2022 135,14 136,49 134,89 135,55 -0,12% 1,18% 4.337.100
29/08/2022 136,20 136,72 134,76 135,71 -0,47% 1,44% 3.835.800
26/08/2022 138,89 139,85 136,25 136,35 -2,14% 2,59% 3.838.800
25/08/2022 138,77 139,56 137,67 139,33 +1,03% 1,36% 3.301.200
24/08/2022 139,05 139,46 137,70 137,91 -0,80% 1,27% 5.018.900
23/08/2022 139,65 140,85 138,45 139,02 -0,94% 1,72% 3.768.100
22/08/2022 141,97 142,66 139,96 140,34 -1,06% 1,90% 4.023.500
19/08/2022 141,78 143,36 141,46 141,85 +0,40% 1,34% 4.530.700
18/08/2022 141,49 141,58 139,82 141,29 -0,11% 1,24% 3.525.200
17/08/2022 141,42 142,76 140,55 141,44 -0,78% 1,56% 3.605.200
16/08/2022 142,11 143,98 142,08 142,55 +0,18% 1,34% 3.852.300
15/08/2022 143,11 143,28 140,42 142,29 -0,22% 2,00% 4.513.200
12/08/2022 141,89 143,09 140,27 142,60 +0,37% 1,99% 5.208.700